.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after an average consequence of 11 months, clients with metastatic stomach cysts that acquired biomarker-matched therapies based on spreading tumor DNA profiling revealed a greater clinical benefit than those obtaining unrivaled therapy.